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Dr Christopher J. Kwolek (Newton, Mass). I would like to
congratulate Drs Sachs and Schermerhorn on bringing us another
interesting paper utilizing large administrative databases, such as
the National Inpatient Sample, to gain a better understanding of
what is occurring nationally in the open and endovascular manage-
ment of type B thoracic aortic dissection. I would also like to thank
the authors for providing me with a copy of their manuscript in a
timely fashion.
Dr Sachs and colleagues have shown that use of thoracic endo-
vascular aortic repair (TEVAR) leads to a decreased in-hospital mor-
tality of 13% compared with an openmortality of 20% for emergent
repair of type B dissection, and a decreased mortality of 4.8% vs
12.8% for elective open repair. This occurred despite the fact that
the TEVAR procedures were being performed on older patients
with greater comorbidities.
The authors have accurately pointed out the limitations of
using administrative databases, including the inability to drill down
on specific details about individual patients, including indications
for surgery, such as visceral malperfusion or aneurysmal dilatation,
and the details about the operative or endovascular repair. In
addition, they have pointed out the coding inaccuracies in these
databases with respect to determining comorbidities, outcomes,
and even the specific types of procedures being performed. Never-
theless, these results agree with the data presented by the European
Collaborators on Stent-Graft Techniques for Aortic Aneurysm
Repair (EUROSTAR) collaborators and several small single-center
series. Our practice at the Massachusetts General Hospital also
utilizes TEVAR as the first-line therapy for the management of
acute complicated type B aortic dissection in conjunction with
endovascular fenestration and stenting of the visceral and iliac
vessels as necessary.
I have several comments/questions for the authors:
1. Since the majority of patients with uncomplicated Type B
dissection are initially treated with medical management, is it
possible to compare the outcomes of these patients using the
same databases?
2. Management of chronic type B dissections is often performed
months or years after the initial dissection and often for aneu-
rysmal degeneration. Yet, your analysis excluded patients with a
diagnosis of both dissection and thoracic aneurysm, thus you
may be missing some of these chronic patients. Furthermore, inexcluded any patients undergoing open repair with cardioplegia
or cardiac assist. Yet, this will miss the patients undergoing open
repair for chronic dissection using atriofemoral bypass to min-
imize the risk of paraplegia and visceral ischemia.
3. You state that any admissions that had both an open and a
TEVAR code were considered a failure of TEVAR that was
converted to open. While the numbers are small, this may also
represent combined procedures where an open and an endo-
vascular hybrid procedure are being performed together and
may begin to occur more frequently in the future.
4. Since the majority of patients with uncomplicated type B dis-
section are initially treated with medical management, is it
possible to compare the outcomes of these patients using the
same databases?
Dr Teviah Sachs. Thank you, Dr Kwolek, those are all very
valid points you bring up. For your first question: Although it is
possible to look at these patients, it was not the focus of our study.
However, if one were to look at those patients, we expect it would
be difficult to exclude type A dissections in this database, as our
methodology excludes type A dissections based on surgical proce-
dure codes. Therefore, we would expect the mortality to be
over-estimated as most type A dissections who are not operated
upon, die.
As to your second question: Our purpose was to analyze the
national outcomes for acute type B dissections and to that end we
did exclude those patients you mentioned, which were more likely
chronic dissections. As for those patients using atriofemoral by-
pass, we don’t expect to have missed those patients. There are
separate codes for cardiopulmonary bypass, which are distinct from
cardioplegia and circulatory arrest, as would be used in atriofemo-
ral bypass procedures.
Your third question, regarding hybrid or staged procedures:
You rightly point out that these could have been combined proce-
dures. However, there were relatively few patients (50), and
rather than exclude these patients, we chose to include them as
“intention to treat.” Since they could have been included in either
group, and would likely bias that group’s mortality, we chose to
bias against TEVAR. As a matter of fact, when isolated, their
outcomes were actually worse than either cohort: open or endo-
vascular.
